Optometry and vision science : official publication of the American Academy of Optometry · 2010
Use of Acular LS in the pain management of keratoconus: a pilot study.
Сравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Jessica O, Gundel Ralph E
Аннотация
PURPOSE: The purpose of this pilot study was to determine the efficacy of ketorolac tromethamine 0.4% for pain management in conjunction with rigid gas permeable contact lenses in keratoconus. Any potential side effects and complications of this application were examined.
METHODS: A total of 12 current keratoconus patients who were presently experiencing discomfort or pain associated with their rigid gas permeables for keratoconus and/or who were contact lens-intolerant were identified from the existing patient population at the SUNY University Optometric Center. Symptomatic subjects were identified through positive feedback to a study Inclusion Questionnaire mailed to their homes. Subjects were treated on the basis of each eye separately in a modified monocular trial that spanned 5 weeks. After establishing that all inclusion and exclusion criteria were met, subjects were instructed to first use an unlabeled bottle of artificial tear solution (placebo) for 2 weeks, and then an unmarked bottle of ketorolac tromethamine 0.4% for 2 weeks in the designated eye. One drop was instilled twice a day, and the eye not assigned to take the drops served as the control. Subjects were monitored through weekly follow-up visits and repeated Keratoconus Symptom and Severity Questionnaires.
RESULTS: Responses from the Keratoconus Symptom and Severity Questionnaire were analyzed using a 2-factor Repeated Measures Analysis of Variance. Among the small subject subset, there was no statistically significant predilection for the ketorolac tromethamine 0.4% in managing the discomfort and pain associated with keratoconus. The artificial tear solution appeared to be equally effective in improving comfort.
CONCLUSIONS: There was no conclusive result as to the efficacy of the ketorolac tromethamine 0.4% vs. the artificial tear solution in the pain management of keratoconus. This could be attributed to a number of physiological and situational factors, as well as small sample size.
METHODS: A total of 12 current keratoconus patients who were presently experiencing discomfort or pain associated with their rigid gas permeables for keratoconus and/or who were contact lens-intolerant were identified from the existing patient population at the SUNY University Optometric Center. Symptomatic subjects were identified through positive feedback to a study Inclusion Questionnaire mailed to their homes. Subjects were treated on the basis of each eye separately in a modified monocular trial that spanned 5 weeks. After establishing that all inclusion and exclusion criteria were met, subjects were instructed to first use an unlabeled bottle of artificial tear solution (placebo) for 2 weeks, and then an unmarked bottle of ketorolac tromethamine 0.4% for 2 weeks in the designated eye. One drop was instilled twice a day, and the eye not assigned to take the drops served as the control. Subjects were monitored through weekly follow-up visits and repeated Keratoconus Symptom and Severity Questionnaires.
RESULTS: Responses from the Keratoconus Symptom and Severity Questionnaire were analyzed using a 2-factor Repeated Measures Analysis of Variance. Among the small subject subset, there was no statistically significant predilection for the ketorolac tromethamine 0.4% in managing the discomfort and pain associated with keratoconus. The artificial tear solution appeared to be equally effective in improving comfort.
CONCLUSIONS: There was no conclusive result as to the efficacy of the ketorolac tromethamine 0.4% vs. the artificial tear solution in the pain management of keratoconus. This could be attributed to a number of physiological and situational factors, as well as small sample size.